Forekomsten af hjertesvigt i det dobbeltblinde hovedstudie var 1, 4% ved tripel - kombinationsbehandling, sammenlignet med 0, 4% for kombinationsbehandling med metformin og sulfonylurinstof.
The incidence of heart failure on triple oral therapy was 1.4% in the main double blind study, compared to 0.4% for metformin plus sulphonylurea dual therapy.